CN
Search Within
C4438
应用筛选条件
关键词:'C4438'
显示 1-30 共 77 条结果 关于 "C4438" 范围 论文
Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis.
Michael Bennett et al.
British journal of haematology, 160(4), 420-420 (2012-12-05)
Z Adam et al.
Vnitrni lekarstvi, 58(6), 455-465 (2012-08-24)
Cladribine (2-chlorodeoxyadenosine) is metabolised and phosphorylated in a cell up to 2-chloroadenosine triphosphate which is the actual effective form of the drug. The greatest accumulation of 2-chloroadenosine triphosphate is in the most active cells, where activating (phosphorylation) enzyme, deoxycytidine kinase
Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
V Vergote et al.
Annals of hematology, 93(12), 2087-2089 (2014-05-28)
Ana de Lorenzo-Pinto et al.
Medicina clinica, 140(2), 76-82 (2012-07-07)
Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system considered the second cause of disability in young adults. The prognosis of MS has improved significantly since the approval of the first interferon β in 1993 but
[Use of 2-chloro-2'-deoxyadenosine (2-CdA) in therapy of hematologic diseases].
M Komarnicki et al.
Polskie Archiwum Medycyny Wewnetrznej, 90(1), 68-71 (1993-07-01)
BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
David Michonneau et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(35), e117-e121 (2014-02-26)
Clemens Warnke et al.
Clinical immunology (Orlando, Fla.), 142(1), 68-75 (2011-07-08)
There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral
Joshua D Rosenberg et al.
Blood, 123(2), 177-183 (2013-11-07)
Hairy cell leukemia (HCL) is a rare, indolent B-cell disorder in which single courses of cladribine induce high rates of complete responses. We report on 88 young HCL patients (≤40 years of age at diagnosis) treated with cladribine from the
Jorge E Cortes et al.
Cancer, 121(2), 234-242 (2014-09-17)
CPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy. This phase II study randomized 125 patients 2:1 to CPX-351 or investigators' choice of first salvage chemotherapy. Patients with acute
V Singh et al.
Clinical and experimental immunology, 173(2), 288-297 (2013-04-24)
2-Chlorodeoxyadenosine (cladribine, CdA) is an immunosuppressive drug that is licensed to treat hairy cell leukaemia, and has been shown recently to have beneficial effects in patients with multiple sclerosis (MS). The therapeutic effects of CdA have been suggested to be
Gunnar Juliusson et al.
Leukemia & lymphoma, 52 Suppl 2, 46-49 (2011-05-27)
Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The
Xiaoshen Sun et al.
British journal of haematology, 168(3), 371-383 (2014-10-07)
Natural killer (NK) large granular lymphocyte (LGL) leukaemia features a clonal proliferation of CD3(-) NK cells that can be classified into either aggressive or chronic categories. The NKL cell line, derived from an aggressive Asian NK cell leukaemia, and patient
Patricia Hentosh et al.
Expert opinion on drug metabolism & toxicology, 6(1), 75-81 (2009-12-09)
Understanding fully the mechanism(s) of action of current and novel anticancer drugs is essential to optimize treatment regimens for oncology patients, to improve or extend drug efficacy and reduce patient side effects. Nucleoside analogues, either alone or in combination with
E Van Den Neste et al.
Leukemia & lymphoma, 40(5-6), 541-550 (2001-06-28)
The purine nucleoside analogs fludarabine and 2-chloro-2'-deoxyadenosine display substantial activity in the treatment of various chronic lymphoproliferative disorders. Their major toxicities are primarily immunosuppression and myelosuppression. The profound influence of these drugs on the immune system has raised questions as
Haematological cancer: The rule of three in AML induction--is cladribine the answer?
Frederick R Appelbaum
Nature reviews. Clinical oncology, 9(7), 376-377 (2012-06-20)
Z Adam et al.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 25(4), 255-261 (2012-08-28)
The effectiveness of cladribine depends on the ratio of activating (deoxycytidine kinase) and inactivating (5-nucleotidase) enzymes. Not only is this ratio high in resting lymphocytes but also in Langerhans cells as well in some other histiocytic cells. Therefore, cladribine shows
J Liliemark et al.
Archivum immunologiae et therapiae experimentalis, 42(1), 7-10 (1994-01-01)
2-Chloro-2'-deoxyadenosine (CdA) is a new antimetabolite with very promising effect in the treatment of chronic lymphoproliferative diseases. It has also been shown to have good activity in acute myelogenous leukemia in children. CdA induces DNA single strand breaks and poly(ADP)-ribosylation
Johan Vande Voorde et al.
Molecular pharmacology, 84(6), 865-875 (2013-09-27)
A mycoplasma-encoded purine nucleoside phosphorylase (designated PNPHyor) has been cloned and characterized for the first time. Efficient phosphorolysis of natural 6-oxopurine and 6-aminopurine nucleosides was observed, with adenosine the preferred natural substrate (Km = 61 µM). Several cytostatic purine nucleoside
L Bastin-Coyette et al.
Biochemical pharmacology, 81(5), 586-593 (2010-12-21)
Nucleoside analogs (NAs) represent an important class of anticancer agents that induce cell death after conversion to triphosphate derivatives. One of their most important mechanisms of action is the activation of p53, leading to apoptosis through the intrinsic pathway. Classically
2-Chloro-2'-deoxyadenosine.
A Delannoy et al.
Acta clinica Belgica, 50(4), 193-196 (1995-01-01)
Pier Luigi Zinzani et al.
Annals of hematology, 93(9), 1565-1569 (2014-04-23)
Hairy cell leukemia (HCL) patients could have an excellent prognosis with adequate treatment. Treatments are not generally curative but are extremely effective in inducing long-lasting clinical remissions. An observational retrospective study was conducted on a single-center registry of 144 patients
Naveen Mulakayala et al.
European journal of medicinal chemistry, 60, 170-186 (2013-01-08)
Multiple sclerosis (MS) often results in chronic inflammatory and autoimmune disorders, and recent developments in understanding the disease pathogenesis has lead to newer therapeutic options for the treatment of the disease. The development of small molecule drugs with improved efficacy
Craig W Freyer et al.
American journal of hematology, 90(1), 62-72 (2014-10-07)
Originally studied in lymphoid diseases, cladribine (CdA) is an adenosine deaminase resistant analog of adenosine that was later discovered to induce myeloid cell apoptosis. The activity of CdA in myeloid malignancies was first reported in relapsed/refractory (RR) pediatric acute myeloid
Małgorzata Rogalińska et al.
Cancer biology & therapy, 14(1), 6-12 (2012-11-02)
The differences in clinical course of chronic lymphocytic leukemia could have an impact on variations in a patient's response to therapy. Our published results revealed that thermal transition (95 ± 5°C) in differential scanning calorimetry profiles appear to be characteristic
Birgit Hecht
Medizinische Monatsschrift fur Pharmazeuten, 33(4), 120-130 (2010-05-01)
Orally disposable drugs for the treatment of multiple sclerosis have been research topics for long-term. Actually there are several drugs in clinical trial. Their mode of action differs among themselves and from established therapeutic agents. While cladribine acts as an
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Sascha Dietrich et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), e300-e303 (2013-05-22)
K Fabianowska-Majewska et al.
Acta poloniae pharmaceutica, 53(4), 231-239 (1996-07-01)
The studies on the metabolism and toxic mechanism of 2-chloro-2'-deoxyadenosine (2CdA, Cladribine), a new antileukemic drug, were reviewed. 2CdA, being a 2-halogenated, adenosine deaminase-resistant analogue of deoxyadenosine, is phosphorylated to the mono-, di, and triphosphate chlorodeoxy adenosine and the first
Darren S Sigal et al.
Blood, 116(16), 2884-2896 (2010-07-17)
Before the contemporary development of rationally designed antineoplastic therapies, cladribine was identified as a lymphocyte-specific agent. Its profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and a median duration of response of nearly a
Almudena Matito et al.
International archives of allergy and immunology, 167(1), 47-56 (2015-07-15)
The role of anesthesia as an elicitor of mast cell (MC) mediator release symptoms in mastocytosis is poorly investigated. To determine the frequency and type of MC mediator release symptoms during anesthetic procedures in mastocytosis patients. Medical records were reviewed
Victoria J Muir et al.
CNS drugs, 25(3), 239-249 (2011-02-18)
Cladribine, an immunosuppressant that selectively reduces peripheral lymphocyte levels, has potential as an oral therapy for relapsing-remitting multiple sclerosis. An oral (tablet) formulation is being investigated in clinical trials. In the large, well designed, phase III CLARITY trial, short-course treatment
1/3